<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30157929</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1478-6362</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>20</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Arthritis research &amp; therapy</Title>                <ISOAbbreviation>Arthritis Res. Ther.</ISOAbbreviation>            </Journal>            <ArticleTitle>The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden.</ArticleTitle>            <Pagination>                <MedlinePgn>190</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-018-1697-6</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hyperuricemia (HU) is in the causal pathway for developing clinical gout. There are few population-based assessments of the absolute and relative risk of clinically diagnosed incident gout in subjects with HU. We aimed to explore the long-term risk of developing incident gout among asymptomatic adults with different levels of serum urate (SU).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Malmö Preventive Project was a population-based screening program for cardiovascular risk factors, alcohol abuse, and breast cancer in Malmö, Sweden. The study population was screened between 1974 and 1992. At baseline, subjects were assessed with a questionnaire, physical examination, and laboratory tests. Follow-up ended at first gout diagnosis, death, moving from area, or December 31, 2014. Incident gout (using ICD10 codes) was diagnosed based on national registers for specialized inpatient and outpatient care, and from 1998 onward in the Skåne Healthcare Register including primary healthcare. Incidence rates, absolute risk, hazard ratios (HRs) and potentially associated factors were analyzed by baseline SU levels, i.e. normal levels (≤ 360 μmol/L); 361-405 (levels below tissue solubility of SU), and &gt; 405 (HU), overall, and by sex.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 1275 individuals [3.8%; 1014 men (4.5%) and 261 women (2.4%)] of the 33,346 study participants (mean age: 45.7 (SD: 7.4), 67% men), developed incident gout during follow-up (mean 28.2 years). Of those with HU, 14.7% of men and 19.5% of women developed gout. Compared to subjects in the lowest SU category, the age-adjusted HR in men increased from 2.7 to 6.4, and in women from 4.4 to 13.1 with increasing baseline SU category, and with a statistically significant interaction of sex (p &lt; 0.001). Body mass index, estimated glomerular filtration rate (negative), triglycerides, alcohol risk behavior (only in men), and comorbidities such as hypertension, cardiovascular disease, and diabetes were strongly associated with SU at baseline in both sexes.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The absolute risk for developing clinically diagnosed gout over 30 years in middle-aged subjects was 3.8%, and increased progressively in both men and women in relation to baseline SU. This risk increase was significantly higher in women than in men, whereas the associations between baseline risk markers and SU levels were similar in both sexes.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kapetanovic</LastName>                    <ForeName>Meliha C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Sciences Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Kioskgatan 5, SE-221 85, Lund, Sweden. meliha.c_kapetanovic@med.lu.se.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nilsson</LastName>                    <ForeName>Peter</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Sciences, Lund University, Malmö, Sweden.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Emergency and Internal Medicine, Skåne University Hospital, Malmö, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Turesson</LastName>                    <ForeName>Carl</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Sciences, Malmö, Lunds University and Skåne University Hospital, Malmö, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Englund</LastName>                    <ForeName>Martin</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Epidemiology Unit, Orthopaedics, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dalbeth</LastName>                    <ForeName>Nicola</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, University of Auckland, Auckland, New Zealand.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jacobsson</LastName>                    <ForeName>Lennart</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Arthritis Res Ther</MedlineTA>            <NlmUniqueID>101154438</NlmUniqueID>            <ISSNLinking>1478-6354</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Intern Med. 2000 Jan;247(1):19-29</RefSource>                <PMID Version="1">10672127</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Med. 1987 Mar;82(3):421-6</RefSource>                <PMID Version="1">3826098</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Rheum. 2010 Apr;62(4):1069-76</RefSource>                <PMID Version="1">20131266</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Epidemiol Rep. 2017;4(4):330-345</RefSource>                <PMID Version="1">29226067</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Rheum. 1972 Mar-Apr;15(2):189-92</RefSource>                <PMID Version="1">5027604</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Rheumatol. 2014 Apr;33(4):549-53</RefSource>                <PMID Version="1">24522482</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Rheumatol. 2015 Nov;11(11):649-62</RefSource>                <PMID Version="1">26150127</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Care Res (Hoboken). 2011 Jan;63(1):102-10</RefSource>                <PMID Version="1">20824805</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Kidney Dis. 2018 Jun;71(6):851-865</RefSource>                <PMID Version="1">29496260</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prev Med. 2015 Dec;81:387-91</RefSource>                <PMID Version="1">26500085</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Res Ther. 2017 Jul 24;19(1):173</RefSource>                <PMID Version="1">28738835</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biomed Res Int. 2015;2015:762820</RefSource>                <PMID Version="1">26640795</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Rheumatol. 2017 Mar;44(3):388-396</RefSource>                <PMID Version="1">28148699</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Obes (Lond). 2015 Jan;39(1):169-75</RefSource>                <PMID Version="1">24798033</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hypertension. 2017 Jun;69(6):1036-1044</RefSource>                <PMID Version="1">28396536</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Rheumatol. 2016 Aug;12(8):486-96</RefSource>                <PMID Version="1">27411906</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2004 Apr 17;363(9417):1277-81</RefSource>                <PMID Version="1">15094272</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2011;6(5):e19901</RefSource>                <PMID Version="1">21625475</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Nephrol. 2014 Jul 27;15:122</RefSource>                <PMID Version="1">25064611</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Kidney Dis. 2017 Aug;70(2):173-181</RefSource>                <PMID Version="1">28410765</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Physiol. 2018 Jan;233(1):88-97</RefSource>                <PMID Version="1">28181253</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Rheum Dis. 2014 Aug;73(8):1470-6</RefSource>                <PMID Version="1">24590182</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Arthritis Rheum. 2017 Feb;46(4):457-464</RefSource>                <PMID Version="1">27591828</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Heart Assoc. 2014 Mar 13;3(2):e000157</RefSource>                <PMID Version="1">24627417</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Med Res Opin. 2015;31 Suppl 2:3-7</RefSource>                <PMID Version="1">26414730</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prev Med. 1983 May;12(3):397-402</RefSource>                <PMID Version="1">6878198</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Care Res (Hoboken). 2016 May;68(5):660-6</RefSource>                <PMID Version="1">26714267</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ Open. 2015 Apr 13;5(4):e006843</RefSource>                <PMID Version="1">25869687</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Clin Biochem. 1982 Sep;19(Pt 5):345-9</RefSource>                <PMID Version="1">6127979</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Rheum Dis. 2016 Apr;76(4):688-693</RefSource>                <PMID Version="1">28076240</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>RMD Open. 2016 Nov 1;2(2):e000326</RefSource>                <PMID Version="1">27933209</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Rheumatol. 2012 Feb;31(2):239-45</RefSource>                <PMID Version="1">21761146</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Res Ther. 2016 Jul 13;18:164</RefSource>                <PMID Version="1">27412614</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Scand J Clin Lab Invest. 2011 May;71(3):232-9</RefSource>                <PMID Version="1">21391777</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Addict. 1982 Sep;77(3):297-304</RefSource>                <PMID Version="1">6128016</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Res Ther. 2017 Jan 17;19(1):6</RefSource>                <PMID Version="1">28095891</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Rheum Dis. 2005 Feb;64(2):267-72</RefSource>                <PMID Version="1">15647434</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Rheumatol. 2000 Apr;27(4):1045-50</RefSource>                <PMID Version="1">10782835</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Rheum Dis. 2018 Jul;77(7):1048-1052</RefSource>                <PMID Version="1">29463518</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arthritis Rheum. 2011 Oct;63(10):3136-41</RefSource>                <PMID Version="1">21800283</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2010 Jun;120(6):1939-49</RefSource>                <PMID Version="1">20501947</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Hyperuricemia</Keyword>            <Keyword MajorTopicYN="N">Incident gout</Keyword>            <Keyword MajorTopicYN="N">Risk factors</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30157929</ArticleId>            <ArticleId IdType="doi">10.1186/s13075-018-1697-6</ArticleId>            <ArticleId IdType="pii">10.1186/s13075-018-1697-6</ArticleId>            <ArticleId IdType="pmc">PMC6116499</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>